Cardiosense, a Chicago-based healthcare technology firm, has achieved a significant regulatory milestone for its innovative heart failure care solution. The U.S. Food & Drug Administration (FDA) has granted De Novo classification for the company's PCWP Analysis Software™. This first-of-its-kind technology provides a noninvasive method to estimate a critical indicator of heart health, paving the way for more proactive and accessible patient management.
Revolutionizing Cardiac Monitoring
For individuals living with heart failure, the buildup of fluid is a primary cause of hospitalization and symptomatic decline. A key metric, pulmonary capillary wedge pressure (PCWP), often signals this fluid accumulation long before a patient feels unwell. This provides a crucial window for medical intervention, but until now, measuring PCWP required an invasive catheter or an implanted device placed directly within the heart.
AI-Powered Noninvasive Assessment
Cardiosense's newly authorized software fundamentally changes this paradigm by leveraging artificial intelligence to deliver precise PCWP estimations. The system works in conjunction with a small, wearable sensor worn on the chest, eliminating the need for invasive procedures. This breakthrough enables clinicians to monitor patients more frequently and detect rising pressure earlier, facilitating timely adjustments to therapy and potentially preventing severe health episodes.
A Milestone for Patient Care
Eric Meizlish, Chief Executive Officer of Cardiosense, described the De Novo classification as a transformative milestone for the company. He emphasized that the technology empowers healthcare providers to make more informed and individualized therapy adjustments for their patients. The ultimate goal is to prevent hospitalizations, support quicker discharge, and significantly improve the quality of life for those managing chronic heart failure.
The Science of Pressure-Guided Therapy
The technology's development is the result of extensive multidisciplinary research and engineering efforts. Omer Inan, PhD, Co-Founder and Chief Scientific Officer, noted the technical achievement of being the first to noninvasively estimate these critical cardiac pressures. He stated that this innovation has the potential to extend pressure-guided care to a much broader patient population, both inside and outside of hospital settings.
Regulatory Pathway and Future Ambitions
This authorization specifically applies to adult patients diagnosed with heart failure with reduced ejection fraction (HFrEF) and NYHA Class II, III, or IV symptoms. The software's clearance follows the FDA 510(k) clearance of the company's CardioTag™ wearable sensor, which was granted in July 2025. Cardiosense is now focused on bringing its comprehensive monitoring solution to patients and their care providers across the country.
Looking ahead, the company plans to continue its mission of patient-first innovation by expanding its technological capabilities. Cardiosense intends to introduce a series of new algorithms designed to detect heart failure earlier. Furthermore, it aims to develop solutions for managing heart failure with preserved ejection fraction (HFpEF), another common form of the condition.
The FDA's De Novo classification for Cardiosense's PCWP Analysis Software marks a pivotal moment in cardiovascular medicine. By providing a safe, noninvasive, and accurate tool for monitoring a key heart failure indicator, the technology promises to enhance clinical decision-making. This advancement offers new hope for improving outcomes and daily life for millions of patients affected by this challenging chronic condition.